ArticleFrontiers in bioengineering and biotechnology2022
Scalable Biofabrication: A Perspective on the Current State and Future Potentials of Process Automation in 3D-Bioprinting Applications.
Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 35 citations in OpenAlex.
- Review
- From Nature to Innovation: Exploring Natural Biopolymers in 3D Bioprinting for Bone Regeneration.ACS omega · 2026Article
- Review
- Investigation of Methacryloyl-Modified Gelatin-Based Hydrogels for Inkjet-Printed Biosensors and Their Adherence to Polyethylene Terephthalate and Oriented Polypropylene Substrates.Engineering in life sciences · 2026Article
- Bioengineering of Periodontal Tissues: Cell Therapy and Biomaterials Application.Bioengineering (Basel, Switzerland) · 2025Review
- Revolutionizing cancer care: Bioprinting prostate cancer stem cells for targeted treatments.World journal of clinical oncology · 2025Review
- Clickable PEG-norbornene microgels support suspension bioprinting and microvascular assembly.Acta biomaterialia · 2025Article
- Development of a robotic-assisted handling and manipulation system for the high-scale bioproduction of 3D-bioprinted organ-on-a-chip devices.HardwareX · 2024Article
- Foods of the Future: Challenges, Opportunities, Trends, and Expectations.Foods (Basel, Switzerland) · 2024Review
- Exploring Synergistic Effects of Bioprinted Extracellular Vesicles for Skin Regeneration.Biomedicines · 2024Review
- High-Scale 3D-Bioprinting Platform for the Automated Production of Vascularized Organs-on-a-Chip.Advanced healthcare materials · 2024Article
- Advances in 3D printing technology for preparing bone tissue engineering scaffolds from biodegradable materials.Frontiers in bioengineering and biotechnology · 2024Article
- Advances in 3D Bioprinting: Techniques, Applications, and Future Directions for Cardiac Tissue Engineering.Bioengineering (Basel, Switzerland) · 2023Review
- Influence of the physico-chemical bioink composition on the printability and cell biological properties in 3D-bioprinting of a liver tumor cell line.Frontiers in bioengineering and biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofabrication, specifically 3D-Bioprinting, has the potential to disruptively impact a wide range of future technological developments to improve human well-being. Organs-on-Chips could enable animal-free and individualized drug development, printed organs may help to overcome non-treatable diseases as well as deficiencies in donor organs and cultured meat may solve a worldwide environmental threat in factory farming. A high degree of manual labor in the laboratory in combination with little trained personnel leads to high costs and is along with strict regulations currently often a hindrance to the commercialization of technologies that have already been well researched. This paper therefore illustrates current developments in process automation in 3D-Bioprinting and provides a perspective on how the use of proven and new automation solutions can help to overcome regulatory and technological hurdles to achieve an economically scalable production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.